This content is from: Premium
Life Sciences Funds Post Mixed Results in September
Several funds moved closer to breakeven, while others extended their already sharp losses.
It looks like it’s one step back for many of the biopharma and life sciences hedge funds that are desperately trying to return to breakeven.After a roughly three-month rally, many of the strategy’s funds suffered losses in September, extending their already double-digit declines for the year. It was a month
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.